305 related articles for article (PubMed ID: 34000049)
1. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Fraser GL; Obermayer-Pietsch B; Laven J; Griesinger G; Pintiaux A; Timmerman D; Fauser BCJM; Lademacher C; Combalbert J; Hoveyda HR; Ramael S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3519-e3532. PubMed ID: 34000049
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
3. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
[TBL] [Abstract][Full Text] [Related]
4. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.
George JT; Kakkar R; Marshall J; Scott ML; Finkelman RD; Ho TW; Veldhuis J; Skorupskaite K; Anderson RA; McIntosh S; Webber L
J Clin Endocrinol Metab; 2016 Nov; 101(11):4313-4321. PubMed ID: 27459523
[TBL] [Abstract][Full Text] [Related]
5. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women.
Fraser GL; Ramael S; Hoveyda HR; Gheyle L; Combalbert J
J Clin Endocrinol Metab; 2016 Feb; 101(2):417-26. PubMed ID: 26653113
[TBL] [Abstract][Full Text] [Related]
6. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
7. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.
Romero-Ruiz A; Skorupskaite K; Gaytan F; Torres E; Perdices-Lopez C; Mannaerts BM; Qi S; Leon S; Manfredi-Lozano M; Lopez-Rodriguez C; Avendaño MS; Sanchez-Garrido MA; Vazquez MJ; Pinilla L; van Duin M; Kohout TA; Anderson RA; Tena-Sempere M
Hum Reprod; 2019 Dec; 34(12):2495-2512. PubMed ID: 31820802
[TBL] [Abstract][Full Text] [Related]
8. Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men.
Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
Clin Endocrinol (Oxf); 2017 Dec; 87(6):748-756. PubMed ID: 28802064
[TBL] [Abstract][Full Text] [Related]
9. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
11. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
12. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
[TBL] [Abstract][Full Text] [Related]
13. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
[TBL] [Abstract][Full Text] [Related]
14. Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.
Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
Hum Reprod; 2020 Jun; 35(6):1421-1431. PubMed ID: 32510130
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of bioactive follicle-stimulating hormone secretion in women with polycystic ovary syndrome: effects of estradiol and progesterone.
Padmanabhan V; Christman GM; Randolph JF; Kelch RP; Marshall JC; Beitins IZ
Fertil Steril; 2001 May; 75(5):881-8. PubMed ID: 11334898
[TBL] [Abstract][Full Text] [Related]
16. Which hormone tests for the diagnosis of polycystic ovary syndrome?
Robinson S; Rodin DA; Deacon A; Wheeler MJ; Clayton RN
Br J Obstet Gynaecol; 1992 Mar; 99(3):232-8. PubMed ID: 1296589
[TBL] [Abstract][Full Text] [Related]
17. Acute progesterone feedback on gonadotropin secretion is not demonstrably altered in estradiol-pretreated women with polycystic ovary syndrome.
Kim SH; Lundgren JA; Patrie JT; Burt Solorzano CM; McCartney CR
Physiol Rep; 2022 Apr; 10(7):e15233. PubMed ID: 35384387
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
20. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
Neuroendocrinology; 2018; 106(2):148-157. PubMed ID: 28380486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
